Ads
related to: waldman's disease prognosis treatment guidelines cancer survival guide
Search results
Results From The WOW.Com Content Network
The lower legs and feet of a 23-year-old woman with Waldmann’s since infancy. Waldmann disease, also known as Primary Intestinal Lymphangiectasia (PIL), is a rare disease [1] characterized by enlargement of the lymph vessels supplying the lamina propria of the small intestine. [2]
When it occurs in the intestines it is known as intestinal lymphangiectasia, colloquially recognized as Waldmann's disease in cases where there is no secondary cause. [3] The primary defect lies in the inability of the lymphatic system to adequately drain lymph, resulting in its subsequent accumulation and leakage into the intestinal lumen. [ 3 ]
Cancer survival rates vary by the type of cancer, stage at diagnosis, treatment given and many other factors, including country. In general survival rates are improving, although more so for some cancers than others. Survival rate can be measured in several ways, median life expectancy having advantages over others in terms of meaning for ...
Survival rate is a part of survival analysis.It is the proportion of people in a study or treatment group still alive at a given period of time after diagnosis. It is a method of describing prognosis in certain disease conditions, and can be used for the assessment of standards of therapy.
In the United States during 2013–2017, the age-adjusted mortality rate for all types of cancer was 189.5/100,000 for males, and 135.7/100,000 for females. [1] Below is an incomplete list of age-adjusted mortality rates for different types of cancer in the United States from the Surveillance, Epidemiology, and End Results program.
Five-year survival rates can be used to compare the effectiveness of treatments. Use of five-year survival statistics is more useful in aggressive diseases that have a shorter life expectancy following diagnosis, such as lung cancer, and less useful in cases with a long life expectancy, such as prostate cancer.
Progression-free survival (PFS) is "the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse". [1] In oncology , PFS usually refers to situations in which a tumor is present, as demonstrated by laboratory testing, radiologic testing, or clinically.
Thoracic radiotherapy generally begins with the first or second cycle when chemotherapy is used according to most guidelines. [19] The time between the start and the end of chemoradiotherapy is a predicator of survival in limited stage small cell lung cancer, prolongation leads to a decrease in overall survival of 1.9% per week. [20]